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Abstract 
Potency control of inactivated rabies vaccines for human and veterinary application is usually undertaken by 
vaccination-challenge tests (e.g. the mouse potency test). For practical and ethical reasons there is an urgent need to 
replace in vivo potency control procedures, at least in part, by reliable methods of in vitro potency testing. 
Quantitative ELISA s,ystems for potency control were developed using monoclonal antibodies (MAbs) directed to the 
glycoprotein (GP) and to the nucleoprotein (NP) of the virus. Although immuno-capture and competition ELISAs for 
GP measurement had almost equal sensitivity (detection level GP < 0.1 IU), the competition data showed the best 
correlation with potency values when a panel of rabies vaccines for human use was tested (r = 0.88, n = 10). The NP 
values for this panel of vaccines in the competition system (detection level NP < 1 IU) also correlated well with 
potency values (r = 0.90, n = 10). The competition system proved to be best also with liquid adjuvanted veterinary 
rabies vaccines of LEAP, PM, PV and SAD origin. The implementation of ELISA systems for potency control of rabies 
vaccines is discussed. 
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1. Introduction 
According to the recommendations of the 
World Health Organization (WHO, 1992) and the 
European Pharmacopoeia (1985), potency control 
of rabies vaccines for human and animal use is 
carried out generally by mouse potency tests (e.g. 
the NIH potency test) (Seligmann, 1973). How- 
* Corresponding author. Tel.: + 31 10 4088066; fax: + 31 
10 4365145. 
ever, this laborious in vivo vaccination-challenge 
procedure in mice is subject to poor reproducibil- 
ity, mainly due to heterogeneity in mice and chal- 
lenge procedures used (Barth et al., 1988). For 
both practical and ethical reasons, replacement of 
in vivo potency tests by more rapid and more 
reliable in vitro methods for potency control is 
highly desirable. In spite of the formal possibility 
of replacing the mouse potency test by in vitro 
antigenicity control methods (WHO, 1992), no 
such alternative assay is widely used at present. 
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We placed emphasis on the development of 
ELISA procedures which meet the WHO require- 
ments for potency control (WHO, 1992). Newly 
developed monoclonal antibody-based ELISA sys- 
tems are described for direct quantification of the 
glycoprotein (GP) and nucleoprotein (NP), which 
constitute the major immunogenic omponents of 
rabies vaccines. The results of antigenicity testing 
of a panel of dog kidney cell-culture rabies vaccines 
by the ELISAs are described and the correlation 
with potency values obtained in the NIH potency 
test is evaluated. Furthermore, the application of 
the ELISAs for testing the antigenicity of veteri- 
nary vaccines of different origins with different 
adjuvants is evaluated. 
2. Materials and methods 
2.1. Rabies vaccines 
Freeze-dried inactivated human rabies vaccines 
of the Pitman-Moore strain propagated on pri- 
mary dog kidney cells (PM-DKC), produced rou- 
tinely at the National Institute of Public Health 
and Environmental Protection (RIVM, Bilthoven, 
The Netherlands), and commercial liquid inacti- 
vated (cell culture) veterinary rabies vaccines of 
various origin (strains PV, SAD, PM, Flury-LEP) 
were stored in a refrigerator until use. 
The 5th International Standard for Rabies Vac- 
cine (Lyng et al., 1992) containing 16 international 
units (IU) of rabies vaccine (potency value 16 IV), 
10 IU of rabies PM-glycoprotein (GP value 10 IU) 
and 135 IU of rabies PM-nucleoprotein (NP value 
135 IV) per ampoule, and the in-house RIVM 
reference rabies vaccine (RO-41A, potency value 
4.2 IU), were used as reference for the NIH 
potency test and the ELISA systems developed in 
the course of these studies. 
2.2. Potency test 
The mouse potency test was carried out follow- 
ing a standardized operating procedure, essentially 
according to the WHO protocol for human rabies 
vaccines (NIH potency test, Seligmann, 1973). 
Briefly, SPF outbred NIH mice (strain Riv:NIH) 
(Hendriksen et al., 1994), were at the age of 4 
weeks, distributed randomly in groups of 20 ani- 
mals (one sex/group). Freshly prepared serial 5- 
fold dilutions of rabies vaccines (samples and 
in-house reference) were used for intraperitoneal 
immunization (0.5 ml doses) of mice on day 0 and 
day 7. On day 14 each mouse was challenged 
intracerebrally with 30 ~1 rabies virus CVS-26 and 
observed daily during 2 weeks for the development 
of rabies symptoms. 
The challenge dose (LD,,) of CVS-26 was ti- 
trated in control mice and calculated according to 
the procedure of Reed and Muench (Lorenz and 
Biigel, 1973). The protective doses (ED,,) were 
calculated according to the Probit analysis of Bliss 
(Bliss, 1935). Vaccine potencies were expressed in 
International Units rabies vaccine (IU RV). 
2.3. Monoclonal antibodies 
Spleen cells isolated from BALB/c mice, immu- 
nized previously with rabies vaccine produced on 
dog kidney cells, were fused with myeloma cells 
(P3-X63-Ag8.653 or Sp2/0) to generate murine 
hybridomas, as described previously (Osterhaus et 
al., 1982). Rabies virus-specific antibody secreting 
hybridomas were selected by ELISA using PM 
virus antigen coated microtiter plates. Single cell 
cloned hybridomas were ultimately propagated in 
vitro. The monoclonal antibodies (MAbs) were 
purified from the cell culture fluids by immuno- 
affinity chromatography on a Protein A or Protein 
G sepharose CL-4-B column (Pharmacia, Uppsala, 
Sweden). Eluted Ig was concentrated by the precip- 
itation method with saturated ammonium sul- 
phate, essentially as described previously (Hong et 
al., 1994). Murine glycoprotein-specific virus neu- 
tralizing MAbs (GP-MAb) 2-22 and 6-15 have 
been described previously (Bunschoten et al., 
1989), whereas 78-9 was developed in the course of 
this study as described above. 
Human hybridomas, secreting NP-specific MAb 
(NP-MAb) 56 and 105, kindly provided by Dr. P. 
Casali (Department of Pathology, New York Uni- 
versity Medical School, New York, USA), were 
generated from EBV-transformed peripheral B 
lymphocytes (Dietzschold et al., 1990). The human 
MAbs 56 and 105 were produced and purified as 
described above for murine MAbs. 
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MAbs were conjugated to horseradish peroxi- 
dase (HRPO) or to biotin (NHS-D-Biotin; Sigma 
Chemie), essentially according to methods de- 
scribed previously (Nakane and Kawaoi, 1974; 
Bayer and Wilchek, 1980). 
2.4. ELBA: standard procedure 
In general, ELISAs were carried out according 
to standardized operating procedures, resulting in 
optimum conditions for each type of test. Briefly, 
the coating procedure of ELISA plates was car- 
ried out with 100 ~1 aliquots/well (16 h, 4°C). 
Subsequently, the Iplates were washed in a semi- 
automatic washing device using de-ionized water 
containing detergent (Tween 20) and emptied. The 
solid phase was blocked with an excessive amount 
of irrelevant proteins (e.g. BSA) in PBS (150 
pi/well, 1 h, 37”C), to reduce non-specific reac- 
tions. Between the successive steps of sample and 
conjugate incubation (100 pi/well, 1 h, 37”C), the 
plates were washed and emptied. ELISA plates 
were developed by a TMB-based substrate solu- 
tion (100 ~1 per well) and the reaction was 
stopped after 10 min by addition of sulphuric 
acid, as described previously (Groen et al., 1989). 
The absorbance (A’) was measured at wavelength 
450nm (OD,,,), using a spectrophotometer for 
microtiter plates (Titertek Multiscan). 
2.5. Characterization of MAbs by ELISAs 
2.5.1. IdentiJication of GP- and NP-producing 
hybridomas 
Mouse hybridoma cell lines producing antibod- 
ies to the rabies virus GP were identified with the 
Platelia Rabies kit (Sanofi Diagnostics), detecting 
antibodies to GP. Human hybridoma cell lines 
producing antibodies to the rabies virus NP were 
identified by indirect ELISA on NP-antigen 
coated ELISA plates. The NP-antigen, expressed 
by a recombinant baculovirus in insect cells, was 
kindly provided by Dr. F. Makkonen, Public 
Health Service, CDC, Lawrenceville, USA). 
2.5.2. Epitope mapping with GP- and NP-spec@ic 
MAbs 
Competitive binding studies by antibody-inhibi- 
tion ELISAs were carried out to determine epi- 
tope and antigenic site specificity of different GP- 
and NP-specific MAbs available, as described pre- 
viously (Bunschoten et al., 1989). Briefly, ELISA 
plates were coated with a standard preparation of 
rabies virus antigen (PM-DKC vaccine), followed 
by incubation with a GP- or NP-specific MAb 
(inhibitor). Subsequently, the biotin conjugated 
MAb, homologous or heterologous to the in- 
hibitor, was incubated at the specified concentra- 
tion which corresponded to 70% of the maximal 
absorbance (A,,,) in control experiments. The 
reaction of the biotin conjugated MAb without 
inhibitor (Acontrol) was included in the experiments 
as the control. The results of the inhibition 
ELISA were expressed as the percentage of inhibi- 
tion (“XJ inhibition), according to the formula: 
% inhibition = (AcontrOl - At,,,)/A,ontror x 100% 
2.6. Antigen quant$cation by ELISAs 
2.61. Immunocapture GP ELBA 
The immunocapture antibody-sandwich princi- 
ple was used to develop quantitative assays for 
GP measurement, according to the procedure de- 
scribed previously (Osterhaus et al., 1990). Briefly, 
GP-MAb 6-15 or 78-9 (respectively for immuno- 
capture GP ELISA 6-15 and immunocapture GP 
ELISA 78-9) was coated on microtiter plates, 
followed by blocking with irrelevant proteins. 
Subsequently, serial 2-fold dilutions of rabies vac- 
cine were incubated, followed by incubation with 
biotin conjugated MAb 2-22. Subsequently, strep- 
tavidin-HRPO was allowed to bind. 
2.6.2. Competition GP and NP ELISA 
Antigen competition ELISAs for the quantita- 
tive determination of GP and NP contents in 
rabies vaccines were developed with GP-MAb 
2-22 and NP-MAb 56 respectively. Briefly, serial 
2-fold dilutions of rabies vaccine were incubated 
with a previously titrated amount of biotin conju- 
gated MAb 2-22 or 56 in a low binding microtiter 
plate. Subsequently, the vaccine-MAb mixture 
was transferred to an ELISA plate coated with a 
standard preparation of rabies virus antigen (PM- 
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DKC vaccine) to determine the remaining antigen 
binding capacity of the biotin conjugated MAb. 
After incubation and washing, streptavidin- 
HRPO was allowed to bind. 
2.7. Calculation procedures for quantitative 
ELBA systems 
The GP and NP contents of vaccines are ex- 
pressed in IU, with reference to the 5th Intema- 
tional Standard for Rabies Vaccine (Lyng et al., 
1992), supplied by the WHO. 
The antigenicity was calculated by a regression 
analysis method, essentially as described by 
Thraenhart and Ramakrishnan (1990). Briefly, a 
dose response curve for the reference was created 
by plotting the absorbance (Y-axis) as a function 
of the potency value (X-axis). The ‘linear range’ 
of the (sigmoidal) reference curve was identified 
and the equation for this range (reference line) 
was calculated by linear regression analysis and 
used to determine relative potency values of the 
samples. Finally, the relative potency value was 
multiplied by the sample dilution to calculate the 
antigenic value (IU) for GP or NP of the vaccine 
sample. The sensitivity of the respective ELISA 
systems was defined as the relative antigenic value 
for GP or NP determined half-way up the titra- 
tion curve of the reference. 
3. Results 
3.1. Selection of murine and human A4Abs 
The study started with competitive binding 
ELISAs for epitope mapping of murine virus 
neutralizing GP-specific monoclonal antibodies 
(GP-MAb) and human NP-specific monoclonal 
antibodies (NP-MAb) being available. Three GP- 
MAbs (2-22, 6-15 and 78-9) were selected which 
proved to recognize different epitopes on func- 
tionally independent antigenic sites of the rabies 
virus GP, respectively antigenic site I, VI and 
II/III. Two NP-specific MAbs (56 and 105) recog- 
nized different, but spatially related epitopes on 
the rabies virus NP. NP-MAb 56 was selected for 
further studies on account of its higher avidity in 
comparison to NP-MAb 105. 
3.2. Assessment of GP and NP contents in 
PM-DKC vaccines 
Quantification of GP contents in vaccines was 
undertaken by two immunocapture ELISAs (im- 
munocapture GP ELISA 6-15 and immunocap- 
ture GP ELISA 78-9) and one competition 
ELISA (competitive GP ELISA), all using biotin 
conjugated GP-MAb 2-22 as detector antibody. 
NP contents in vaccines were quantitated by a 
competition NP ELISA using biotin conjugated 
NP-MAb 56 as detector antibody. Experimental 
conditions for the respective ELISA systems were 
optimized, which resulted in detection levels for 
GP of 0.03 IU in the immunocapture GP ELISA 
6-15 and 0.05 IU in both the immunocapture GP 
ELISA 78-9 and the competition GP ELISA. The 
detection level for NP by the competition NP 
ELISA was 0.8 IU. 
GP and NP values of ten consecutive produc- 
tion lots of PM-DKC vaccines were assessed by 
the respective ELISAs, using the International 
Standard for rabies vaccine as reference. As 
shown in Table 1, immunocapture GP ELISA 
6-l 5 gives lower GP values than immunocapture 
GP ELISA 78-9 and competition GP ELISA, the 
latter two assays showing similar GP values. 
Antigenic values for GP and NP by the differ- 
ent ELISAs all showed similar correlation with 
potency values established in NIH potency test 
(Fig. l), correlation coeffcients (r) ranged from 
0.71 to 0.90, as indicated in the graphs. 
3.3. Use of ELISA systems for veterinary rabies 
vaccines 
Seven commercial veterinary rabies vaccines 
were titrated by the respective ELISA systems for 
measurement of GP and NP contents (Fig. 2). 
One of the vaccines of SAD origin adjuvanted 
with a carbohydrate polymer (sample 1, Fig. 2) 
could not be evaluated by the different ELISAs: 
absorbancy (OD values) by immunocapture GP 
ELISAs 6-15 and 78-9 were out of range for 
regression analysis, whereas by competition 
ELISAs for GP and NP no parallelism was found 
between titration curves of sample 1 and refer- 
ence. Furthermore, immunocapture GP ELISA 
Table 1 
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GP and NP values (IU) in different ELISAs for ten PM-DKC rabies vaccines 
Vaccine lot no. A ntigenic value 
Immunocapture GP 6- 15 Immunocapture GP 78-9 Competition GP Competition NP 
1 2.1 7.0 6.7 198 
2 13.4 26.8 26.8 718 
3 3.6 9.0 13.2 267 
4 5.2 14.3 20.2 443 
5 0.7 1.8 2.2 97 
6 3.4 8.5 10.5 372 
7 1.7 4.2 5.7 316 
8 13.2 22.4 42.5 1181 
9 10.3 23.5 28.0 1029 
10 13.5 35.6 36.0 1077 
6- 15 could not be used for the LEP vaccine (sam- 
ple 4) and one of tlhe two PV vaccines (sample 5) 
in the panel tested. Coating of these vaccines in 
indirect ELISA with GP-MAb 6-15 proved that 
the respective vaccine strains were not recognized 
by the MAb (data not shown). The other ELISAs 
(immunocapture GP ELISA 78-9, competition 
GP ELISA and competition NP ELISA) could be 
used for all vaccines of PM, PV, SAD (except 
sample 1) and LEP origin involved. Titration 
curves of these vaccines showed lines parallel to 
the titration curve of the International Standard 
for rabies vaccine by the respective ELISAs. 
4. Discussion 
In Europe, millions of human and veterinary 
rabies vaccine doses are produced annually by cell 
culture techniques (Sureau, 1992). These vaccines 
are used world-wide, with the exception of certain 
developing countries where traditional neural tis- 
sue vaccines are produced for local use. Released 
batches of these rabies vaccines should meet the 
international requirements for potency, specified 
by the WHO Expert Committee on Rabies 
(WHO, 1992). Potencies of these vaccines are 
usually determined in in vivo mouse potency tests, 
which require world-wide tens of thousands of 
mice annually, which must be challenged with 
virulent rabies virus. 
There is a consensus amongst control authori- 
ties and manufacturers that a replacement or at 
least a refinement and reduction of such unethical 
animal tests should be sought. Furthermore, the 
clear practical drawbacks (e.g. laborious, time- 
consuming and expensive procedures) and the 
poor intra- and inter-laboratory reproducibility of 
mouse potency tests are subject to substantial 
criticism (Barth et al., 1988). The incentive to 
replace the in vivo potency test is reflected by the 
efforts of numerous laboratories to introduce reli- 
able alternative in vitro methods. This has, how- 
ever, led to only limited numbers of proposals for 
actual replacement. So far, the modified antibody 
binding test (ABT) (Barth et al., 1981; Barth et 
al., 1990) and the single radial diffusion test 
(SRD) (Ferguson and Schild, 1982; Ferguson et 
al., 1984; Ferguson and Heath, 1992) were pro- 
posed as alternatives. Their use is restricted to GP 
measurement by polyclonal antibodies and is not 
applicable to adjuvanted vaccines. The ELISA 
systems described so far for potency estimation 
were all based on polyclonal antibodies against 
the GP or NP (Atanasiu et al., 1980; Van der 
Mare1 and Van Wezel, 1981; Thraenhart and Ra- 
makrishnan, 1989; Perrin et al., 1990) or on 
MAbs specific for GP (Lafon et al., 1985). In our 
view, the methods of choice should measure anti- 
genicity with GP- and NP-MAbs recognizing all 
vaccine strains and should be suitable for final lot 
control of adjuvanted vaccines. 
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Fig. 1. Correlation between results in NIH potency test and different ELISAs for a panel of 10 human PM-DKC rabies vaccines. 
(A,B), immunocapture GP ELISAs 6-15 and 78-9 (sensitivity 0.03 and 0.05 GP units per dose, respectively); (C), competition GP 
ELISA (sensitivity 0.05 GP units per dose); (D), competition NP ELISA (sensitivity 0.8 NP units per dose). Correlation coefficients 
(r) and the regression lines (dotted line) were determined by linear regression analysis and are indicated in the graphs. 
In the present study, we demonstrated the suit- 
ability of MAb-based ELBA techniques for 
quantitation of GP and NP contents in rabies 
vaccines. A good correlation (up to r = 0.88) was 
shown between potency values on the one hand 
and GP values by immunocapture and competi- 
tion ELISAs on the other hand, when PM-DKC 
vaccines were tested. Also good correlation 
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Fig. 2. Titration of veterinary rabies vaccines in immunocapture GP ELISAs 6-l 5 and 78-9, competition GP ELISA and competition 
NP ELBA. The panel of vaccines consisted of seven commercial veterinary rabies vaccines (no.1, SAD polymer adjuvanted; nos. 
2 and 7, SAD; no.3, PM; no.4, LEP; nos.5 and 6, PV) and the International Standard for rabies vaccine (no.8, PM). 
(u = 0.90) was found between potency values and SAD and LEP vaccine strains. First, immunocap- 
NP values by competition NP ELBA for PM- ture GP ELISA 6-15 could not be applied to the 
DKC vaccines. Furthermore, we demonstrated LEP and one of the PV rabies vaccines, which is 
differences of applicability of GP ELISAs to vet- reasonably related to strain-specific differences in 
erinary rabies vaccines produced with FM, PV, antigenic sites on the rabies virus GP. Second, 
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although immunocapture GP ELISA 78-9 and 
competition GP ELISA using MAb 2-22 could 
readily be applied to the different vaccine strains 
tested here, the results of the vaccine titrations 
by the ELISAs appeared to be different. These 
findings indicate that a product-specific reference 
vaccine is probably needed to calibrate the sys- 
tems. Also special attention should be paid to 
adjuvants used in veterinary vaccines. The 
present data show that the results in ELISA for 
one of the SAD vaccines were invalid, which is 
likely caused by the presence of a polymer-based 
adjuvant. 
Taken together, it was shown that in vitro GP 
and NP antigenicity control by ELISA has the 
potential to replace, at least in part, the mouse 
potency test for inactivated rabies vaccines. We 
suggest a further evaluation of the potential of 
the newly developed competition ELISAs in well- 
founded collaborative studies. A rapid start with 
collaborative testing can be made with retrospec- 
tive testing of already released rabies vaccine lots 
by the proposed ELISAs. It should be realized 
that antigenicity of vaccines as measured by 
ELISA systems, can only provide an indication 
of the potency in vivo. Additional support for 
the introduction of in vitro antigenicity ELISA 
systems, may be based on the simultaneous in- 
troduction of in vitro assays demonstrating anti- 
genicity at the T cell level in proliferative T cell 
responses. PM-DKC vaccine induced prolifera- 
tion of lymphoid cells from rabies vaccinated 
individuals showed good correlation with in vivo 
potency values and GP values in the competition 
ELISA presented here (Rooijakkers et al., 1995). 
Also assessment of virus neutralizing-Abs after 
rabies vaccination by a serological assay system, 
which is an important parameter for protection 
against rabies infection (Wunderli et al., 1991), 
should be carried out in the evaluation of alter- 
native methods for the mouse potency test. 
In conclusion, the introduction of alternative 
in vitro assay systems to estimate the potency of 
vaccines may only be considered if the pro- 
duction methods of the vaccine are well stan- 
dardized, a good correlation with protective im- 
munity has been shown and the ELISA systems 
are properly validated. 
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